Skip to main content

Advertisement

SpringerLink
Log in

Bone Health in Parkinson’s Disease

  • Review Paper
  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is a chronic neurodegenerative disease characterized by tremor at rest, bradykinesia, rigidity, and loss of postural reflexes. Patients can also exhibit a plethora of non-motor symptoms, such as autonomic dysfunction, sleep disturbances, and neuropsychiatric comorbidities. In the last years, a growing body of evidence has revealed that PD patients have relevant abnormalities in bone health. A substantial number of studies have shown that PD is associated with an increased risk of fractures, with low bone mineral density and with decreased vitamin D levels in serum. Osteoporosis in PD may be understood as a multifactorial process triggered by several causes, such as immobility or low sunlight exposure. However, several lines of evidence suggest that the presence of PD is associated with osteoporosis, fractures, and vitamin D abnormalities since the early stages of the disease and even before the onset of the motor symptoms. In the clinical setting, it must be kept in mind that fractures in PD patients may have deleterious consequences and even increase their functional impairment. In this regard, the availability of treatment guidelines based on clinical trials is an unmet need. This review summarizes the available studies from the last 26 years that have assessed bone health in PD regarding four major issues: (1) risk and specific features of fractures, (2) bone mineral density, (3) the vitamin D status, and (4) treatment options. In addition to the available literature, we endeavor to provide with insights into future developments in this area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–35. doi:10.1016/S1474-4422(06)70471-9.

    Article  PubMed  Google Scholar 

  2. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007;68(5):326–37. doi:10.1212/01.wnl.0000252807.38124.a3.

    Article  CAS  PubMed  Google Scholar 

  3. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–9.

    Article  CAS  PubMed  Google Scholar 

  4. Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK. The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol. 2016;23(5):854–60. doi:10.1111/ene.12950.

    Article  CAS  PubMed  Google Scholar 

  5. Johnell O, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Kurland LT. Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing. 1992;21(1):32–8.

    Article  CAS  PubMed  Google Scholar 

  6. Kao CH, Chen CC, Wang SJ, Chia LG, Yeh SH. Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun. 1994;15(3):173–7.

    Article  CAS  PubMed  Google Scholar 

  7. Consensus development conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–50.

    Article  Google Scholar 

  8. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81. doi:10.1007/s00198-014-2794-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ. 2000;320(7231):341–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39(2):203–9. doi:10.1093/ageing/afp221.

    Article  PubMed  Google Scholar 

  11. Sambrook P, Cooper C. Osteoporosis Lancet. 2006;367(9527):2010–8. doi:10.1016/S0140-6736(06)68891-0.

    Article  CAS  PubMed  Google Scholar 

  12. Lloyd ME, Spector TD, Howard R. Osteoporosis in neurological disorders. J Neurol Neurosurg Psychiatry. 2000;68(5):543–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Benka Wallen M, Franzen E, Nero H, Hagstromer M. Levels and patterns of physical activity and sedentary behavior in elderly people with mild to moderate Parkinson disease. Phys Ther. 2015;95(8):1135–41. doi:10.2522/ptj.20140374.

    Article  PubMed  Google Scholar 

  14. van Nimwegen M, Speelman AD, Hofman-van Rossum EJ, Overeem S, Deeg DJ, Borm GF, et al. Physical inactivity in Parkinson’s disease. J Neurol. 2011;258(12):2214–21. doi:10.1007/s00415-011-6097-7.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Saravi FD, Sayegh F. Bone mineral density and body composition of adult premenopausal women with three levels of physical activity. J Osteoporos. 2013;2013:953271. doi:10.1155/2013/953271.

    PubMed  PubMed Central  Google Scholar 

  16. Bijelic R, Milicevic S, Balaban J. Risk factors for osteoporosis in postmenopausal women. Med Arch. 2017;71(1):25–8. doi:10.5455/medarh.2017.71.25-28.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bolland MJ, Avenell A, Gamble GD, Grey A. Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology. 2016;87(23):2391–402. doi:10.1212/WNL.0000000000003387.

    Article  PubMed  Google Scholar 

  18. Sato Y, Iwamoto J, Kanoko T, Satoh K. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord. 2006;21(7):924–9. doi:10.1002/mds.20825.

    Article  PubMed  Google Scholar 

  19. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology. 2007;68(12):911–5. doi:10.1212/01.wnl.0000257089.50476.92.

    Article  CAS  PubMed  Google Scholar 

  20. Sato Y, Iwamoto J, Honda Y. Once-weekly risedronate for prevention of hip fracture in women with Parkinson’s disease: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2011a;82(12):1390–3. doi:10.1136/jnnp.2011.244574.

    Article  PubMed  Google Scholar 

  21. Sato Y, Iwamoto J, Honda Y. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson’s disease. Parkinsonism Relat Disord. 2011b;17(1):22–6. doi:10.1016/j.parkreldis.2010.10.008.

    Article  PubMed  Google Scholar 

  22. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease. Am J Med. 2005a;118(11):1250–5. doi:10.1016/j.amjmed.2005.01.052.

    Article  CAS  PubMed  Google Scholar 

  23. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord. 2005b;20(12):1598–603. doi:10.1002/mds.20658.

    Article  PubMed  Google Scholar 

  24. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci. 2001;182(2):89–93.

    Article  CAS  PubMed  Google Scholar 

  25. Sato Y, Kaji M, Tsuru T, Satoh K, Kondo I. Vitamin K deficiency and osteopenia in vitamin D-deficient elderly women with Parkinson’s disease. Arch Phys Med Rehabil. 2002;83(1):86–91.

    Article  PubMed  Google Scholar 

  26. Sato Y, Iwamoto J, Honda Y, Amano N. Vitamin D reduces falls and hip fractures in vascular parkinsonism but not in Parkinson’s disease. Ther Clin Risk Manag. 2013;9:171–6. doi:10.2147/TCRM.S43811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R, Lees AJ. Bone health in Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014;85(10):1159–66. doi:10.1136/jnnp-2013-307307.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Hiorth YH, Larsen JP, Lode K, Tysnes OB, Godfrey A, Lord S, et al. Impact of falls on physical activity in people with Parkinson’s disease. J Parkinsons Dis. 2016a;6(1):175–82. doi:10.3233/JPD-150640.

    Article  PubMed  Google Scholar 

  29. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in Parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord. 2006;12(1):35–41. doi:10.1016/j.parkreldis.2005.06.011.

    Article  PubMed  Google Scholar 

  30. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson’s disease: the relative importance of the symptoms. Mov Disord. 2008;23(10):1428–34. doi:10.1002/mds.21667.

    Article  PubMed  Google Scholar 

  31. Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Parkinsons Dis. 2013;2013:906274. doi:10.1155/2013/906274.

    PubMed  PubMed Central  Google Scholar 

  32. Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS One. 2009;4(5):e5521. doi:10.1371/journal.pone.0005521.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Hiorth YH, Alves G, Larsen JP, Schulz J, Tysnes OB, Pedersen KF. Long-term risk of falls in an incident Parkinson’s disease cohort: the Norwegian ParkWest study. J Neurol. 2016b; doi:10.1007/s00415-016-8365-z.

  34. Lord S, Galna B, Yarnall AJ, Coleman S, Burn D, Rochester L. Predicting first fall in newly diagnosed Parkinson’s disease: insights from a fall-naive cohort. Mov Disord. 2016;31(12):1829–36. doi:10.1002/mds.26742.

    Article  PubMed  Google Scholar 

  35. Kerr GK, Worringham CJ, Cole MH, Lacherez PF, Wood JM, Silburn PA. Predictors of future falls in Parkinson disease. Neurology. 2010;75(2):116–24. doi:10.1212/WNL.0b013e3181e7b688.

    Article  CAS  PubMed  Google Scholar 

  36. Latt MD, Lord SR, Morris JG, Fung VS. Clinical and physiological assessments for elucidating falls risk in Parkinson’s disease. Mov Disord. 2009;24(9):1280–9. doi:10.1002/mds.22561.

    Article  PubMed  Google Scholar 

  37. Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. J Neurol Neurosurg Psychiatry. 2002;72(6):721–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Jonsson B, Sernbo I, Johnell O. Rehabilitation of hip fracture patients with Parkinson’s Disease. Scand J Rehabil Med. 1995;27(4):227–30.

  39. Hochberg MC, Williamson J, Skinner EA, Guralnik J, Kasper JD, Fried LP. The prevalence and impact of self-reported hip fracture in elderly community-dwelling women: the women’s health and aging study. Osteoporos Int. 1998;8(4):385–9. doi:10.1007/s001980050079.

  40. Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing. 2005;34(1):21–4. doi:10.1093/ageing/afh203.

  41. Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE, Osteoporotic Fractures in Men Study G. Association between Parkinson’s disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc. 2005;53(9):1559–64. doi:10.1111/j.1532-5415.2005.53464.x.

    Article  PubMed  Google Scholar 

  42. Idjadi JA, Aharonoff GB, Su H, Richmond J, Egol KA, Zuckerman JD, et al. Hip fracture outcomes in patients with Parkinson's disease. Am J Orthop (Belle Mead NJ). 2005;34(7):341–6.

  43. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry. 2006;77(4):468–73. doi:10.1136/jnnp.2005.074070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Leibson CL, Maraganore DM, Bower JH, Ransom JE, O'Brien PC, Rocca WA. Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord. 2006;21(4):446–55. doi:10.1002/mds.20685.

  45. Melton LJ 3rd, Leibson CL, Achenbach SJ, Bower JH, Maraganore DM, Oberg AL, et al. Fracture risk after the diagnosis of Parkinson’s disease: influence of concomitant dementia. Mov Disord. 2006;21(9):1361–7. doi:10.1002/mds.20946.

    Article  PubMed  Google Scholar 

  46. Lorefalt B, Toss G, Granerus AK. Bone mass in elderly patients with Parkinson’s disease. Acta Neurol Scand. 2007;116(4):248–54. doi:10.1111/j.1600-0404.2007.00875.x.

    Article  CAS  PubMed  Google Scholar 

  47. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int. 2007;81(3):153–61. doi:10.1007/s00223-007-9065-6.

    Article  CAS  PubMed  Google Scholar 

  48. Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE, et al. Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2008;19(9):1277–82. doi:10.1007/s00198-008-0584-4.

    Article  CAS  PubMed  Google Scholar 

  49. Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR, Study of Osteoporotic Fractures Research G. The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int. 2008;19(7):1093–7. doi:10.1007/s00198-008-0583-5.

    Article  CAS  PubMed  Google Scholar 

  50. Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A. Type of hip fracture in patients with Parkinson disease is associated with femoral bone mineral density. Arch Phys Med Rehabil. 2008;89(12):2297–301. doi:10.1016/j.apmr.2008.06.016.

  51. Abou-Raya S, Helmii M, Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson’s disease. Age Ageing. 2009;38(6):675–80. doi:10.1093/ageing/afp137.

    Article  PubMed  Google Scholar 

  52. Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Kim HK, et al. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson’s disease. Calcif Tissue Int. 2010a;86(2):132–41. doi:10.1007/s00223-009-9327-6.

    Article  PubMed  CAS  Google Scholar 

  53. Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Ryu JS, et al. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson’s disease. Mov Disord. 2010b;25(3):332–40. doi:10.1002/mds.22866.

    Article  PubMed  Google Scholar 

  54. Lam K, Li M, Mok V, Hui A, Woo J. A case control study on bone mineral density in Chinese patients with Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(7):471–4. doi:10.1016/j.parkreldis.2010.05.002.

    Article  PubMed  Google Scholar 

  55. Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(7):2197–204. doi:10.1007/s00198-010-1455-3.

    Article  CAS  PubMed  Google Scholar 

  56. Chen YY, Cheng PY, Wu SL, Lai CH. Parkinson’s disease and risk of hip fracture: an 8-year follow-up study in Taiwan. Parkinsonism Relat Disord. 2012;18(5):506–9. doi:10.1016/j.parkreldis.2012.01.014.

    Article  PubMed  Google Scholar 

  57. Bhattacharya RK, Dubinsky RM, Lai SM, Dubinsky H. Is there an increased risk of hip fracture in Parkinson’s disease? A nationwide inpatient sample. Mov Disord. 2012;27(11):1440–3. doi:10.1002/mds.25073.

  58. Walker RW, Chaplin A, Hancock RL, Rutherford R, Gray WK. Hip fractures in people with idiopathic Parkinson's disease: incidence and outcomes. Mov Disord. 2013;28(3):334–40. doi:10.1002/mds.25297.

  59. Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef C, Cooper C, et al. Risk of fracture in patients with Parkinson’s disease. Osteoporos Int. 2013;24(8):2283–90. doi:10.1007/s00198-013-2300-2.

    Article  CAS  PubMed  Google Scholar 

  60. Cheng KY, Lin WC, Chang WN, Lin TK, Tsai NW, Huang CC, et al. Factors associated with fall-related fractures in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(1):88–92. doi:10.1016/j.parkreldis.2013.09.024.

  61. Shribman S, Torsney KM, Noyce AJ, Giovannoni G, Fearnley J, Dobson R. A service development study of the assessment and management of fracture risk in Parkinson’s disease. J Neurol. 2014;261(6):1153–9. doi:10.1007/s00415-014-7333-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Benzinger P, Rapp K, Maetzler W, Konig HH, Jaensch A, Klenk J et al. Risk for femoral fractures in Parkinson’s disease patients with and without severe functional impairment. PLoS One. 2014;9(5):e97073. doi:10.1371/journal.pone.0097073.

  63. Jantzi M, Maher AC, Ioannidis G, Hirdes JP, Giangregorio LM, Papaioannou A. Individuals with neurological diseases are at increased risk of fractures within 180 days of admission to long-term care in Ontario. Age Ageing. 2015;44(2):252–7. doi:10.1093/ageing/afu156.

  64. Huang YF, Cherng YG, Hsu SP, Yeh CC, Chou YC, Wu CH, et al. Risk and adverse outcomes of fractures in patients with Parkinson’s disease: two nationwide studies. Osteoporos Int. 2015;26(6):1723–32. doi:10.1007/s00198-015-3052-y.

  65. Karadsheh MS, Rodriguez EK, Harris MB, Zurakowski D, Lucas R, Weaver MJ. Mortality and revision surgery are increased in patients with Parkinson’s disease and fractures of the femoral neck. Clin Orthop Relat Res. 2015;473(10):3272–9. doi:10.1007/s11999-015-4262-5.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Nystrom H, Nordstrom A, Nordstrom P. Risk of injurious fall and hip fracture up to 26 y before the diagnosis of Parkinson disease: nested case-control studies in a nationwide cohort. PLoS Med. 2016;13(2):e1001954. doi:10.1371/journal.pmed.1001954.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Sleeman I, Che ZC, Counsell C. Risk of fracture amongst patients with Parkinson’s disease and other forms of parkinsonism. Parkinsonism Relat Disord. 2016;29:60–5. doi:10.1016/j.parkreldis.2016.05.026.

    Article  PubMed  Google Scholar 

  68. Tassorelli C, Berlangieri M, Buscone S, Bolla M, De Icco R, Baricich A, et al. Falls, fractures and bone density in Parkinson's disease - a cross-sectional study. Int J Neurosci. 2017;127(4):299–304. doi:10.1080/00207454.2016.1206897.

  69. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;344:e3427. doi:10.1136/bmj.e3427.

    Article  PubMed  Google Scholar 

  70. Gregson CL, Dennison EM, Compston JE, Adami S, Adachi JD, Anderson FA Jr, et al. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int. 2014;25(1):85–95. doi:10.1007/s00198-013-2438-y.

    Article  CAS  PubMed  Google Scholar 

  71. Tan L, Wang Y, Zhou L, Shi Y, Zhang F, Liu L, et al. Parkinson’s disease and risk of fracture: a meta-analysis of prospective cohort studies. PLoS One. 2014;9(4):e94379. doi:10.1371/journal.pone.0094379.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD, et al. Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2012;50(6):1288–93. doi:10.1016/j.bone.2012.02.639.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Schousboe JT. Epidemiology of vertebral fractures. J Clin Densitom. 2016;19(1):8–22. doi:10.1016/j.jocd.2015.08.004.

    Article  PubMed  Google Scholar 

  74. El Maghraoui A, Koumba BA, Jroundi I, Achemlal L, Bezza A, Tazi MA. Epidemiology of hip fractures in 2002 in Rabat. Morocco Osteoporos Int. 2005;16(6):597–602. doi:10.1007/s00198-004-1729-8.

    Article  PubMed  Google Scholar 

  75. Zhao Y, Shen L, Ji HF. Osteoporosis risk and bone mineral density levels in patients with Parkinson’s disease: a meta-analysis. Bone. 2013;52(1):498–505. doi:10.1016/j.bone.2012.09.013.

    Article  PubMed  Google Scholar 

  76. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol. 2003;60(1):59–64.

    Article  PubMed  Google Scholar 

  77. Zoccolella S, Martino D, Defazio G, Lamberti P, Livrea P. Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr Vasc Pharmacol. 2006;4(3):237–43.

    Article  CAS  PubMed  Google Scholar 

  78. Zhu Y, Shen J, Cheng Q, Fan Y, Lin W. Plasma homocysteine level is a risk factor for osteoporotic fractures in elderly patients. Clin Interv Aging. 2016;11:1117–21. doi:10.2147/CIA.S107868.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Kim JI, Moon JH, Chung HW, Kong MH, Kim HJ. Association between homocysteine and bone mineral density according to age and sex in healthy adults. J Bone Metab, 2016. 23(3):129–34. doi:10.11005/jbm.2016.23.3.129.

  80. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem. 2005;51(12):2348–53. doi:10.1373/clinchem.2005.053363.

    Article  CAS  PubMed  Google Scholar 

  81. Moshal KS, Singh M, Sen U, Rosenberger DS, Henderson B, Tyagi N, et al. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol. 2006;291(6):H2825–35. doi:10.1152/ajpheart.00377.2006.

    Article  CAS  PubMed  Google Scholar 

  82. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick’s hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta. 1996;1315(3):159–62.

    Article  PubMed  Google Scholar 

  83. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807–16. doi:10.1007/s00198-005-0065-y.

    Article  CAS  PubMed  Google Scholar 

  84. Haney EM, Warden SJ. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact. 2008;8(2):133–45.

    CAS  PubMed  Google Scholar 

  85. Warden SJ, Haney EM. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J Musculoskelet Neuronal Interact. 2008;8(2):121–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Bradaschia-Correa V, Josephson AM, Mehta D, Mizrahi M, Neibart SS, Liu C, et al. The selective serotonin re-uptake inhibitor fluoxetine directly inhibits osteoblast differentiation and mineralization during fracture healing in mice. J Bone Miner Res. 2016; doi:10.1002/jbmr.3045.

  87. Marques A, Ferreira RJ, Santos E, Loza E, Carmona L, da Silva JA. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1958–67. doi:10.1136/annrheumdis-2015-207907.

    Article  PubMed  Google Scholar 

  88. Lyell V, Henderson E, Devine M, Gregson C. Assessment and management of fracture risk in patients with Parkinson’s disease. Age Ageing. 2015;44(1):34–41. doi:10.1093/ageing/afu122.

    Article  PubMed  Google Scholar 

  89. Ishizaki F, Harada T, Katayama S, Abe H, Nakamura S. Relationship between osteopenia and clinical characteristics of Parkinson’s disease. Mov Disord. 1993;8(4):507–11. doi:10.1002/mds.870080416.

    Article  CAS  PubMed  Google Scholar 

  90. Taggart H, Crawford V. Reduced bone density of the hip in elderly patients with Parkinson’s disease. Age Ageing. 1995;24(4):326–8.

  91. Revilla M, de la Sierra G, Aguado F, Varela L, Jimenez-Jimenez FJ, Rico H. Bone mass in Parkinson’s disease: a study with three methods. Calcif Tissue Int. 1996;58(5):311–5.

    Article  CAS  PubMed  Google Scholar 

  92. Di Monaco M, Vallero F, Di Monaco R, Tappero R, Cavanna A. Bone mineral density in hip-fracture patients with Parkinson’s disease: a case-control study. Arch Phys Med Rehabil. 2006;87(11):1459–62. doi:10.1016/j.apmr.2006.07.265.

  93. Wood B, Walker R. Osteoporosis in Parkinson’s disease. Mov Disord. 2005;20(12):1636–40. doi:10.1002/mds.20643.

    Article  PubMed  Google Scholar 

  94. Fernandez MC, Parisi MS, Diaz SP, Mastaglia SR, Deferrari JM, Seijo M, et al. A pilot study on the impact of body composition on bone and mineral metabolism in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(6):355–8. doi:10.1016/j.parkreldis.2006.12.010.

    Article  PubMed  Google Scholar 

  95. Kamide N, Fukuda M, Miura H. The relationship between bone density and the physical performance of ambulatory patients with Parkinson’s disease. J Physiol Anthropol. 2008;27(1):7–10.

    Article  PubMed  Google Scholar 

  96. Bezza A, Ouzzif Z, Naji H, Achemlal L, Mounach A, Nouijai M, et al. Prevalence and risk factors of osteoporosis in patients with Parkinson’s disease. Rheumatol Int. 2008;28(12):1205–9. doi:10.1007/s00296-008-0632-6.

    Article  CAS  PubMed  Google Scholar 

  97. Kamanli A, Ardicoglu O, Ozgocmen S, Yoldas TK. Bone mineral density in patients with Parkinson’s disease. Aging Clin Exp Res. 2008;20(3):277–9.

    Article  PubMed  Google Scholar 

  98. Pang MY, Mak MK. Trunk muscle strength, but not trunk rigidity, is independently associated with bone mineral density of the lumbar spine in patients with Parkinson’s disease. Mov Disord. 2009;24(8):1176–82. doi:10.1002/mds.22531.

    Article  PubMed  Google Scholar 

  99. Song IU, Kim JS, Lee SB, Ryu SY, An JY, Jeong DS, et al. The relationship between low bone mineral density and Parkinson’s disease in a Korean population. J Clin Neurosci. 2009;16(6):807–9. doi:10.1016/j.jocn.2008.08.027.

    Article  PubMed  Google Scholar 

  100. Daniel SK, Lansang MC, Okun MS. Bone mineral density (BMD) in male patients with Parkinson’s disease. Int J Neurosci. 2012;122(9):523-7. doi:10.3109/00207454.2012.685530.

  101. van den Bos F, Speelman AD, van Nimwegen M, van der Schouw YT, Backx FJ, Bloem BR, et al. Bone mineral density and vitamin D status in Parkinson’s disease patients. J Neurol. 2012; doi:10.1007/s00415-012-6697-x.

  102. Gao H, Wei X, Liao J, Wang R, Xu J, Liu X, et al. Lower bone mineral density in patients with Parkinson’s disease: a cross-sectional study from Chinese mainland. Front Aging Neurosci. 2015;7:203. doi:10.3389/fnagi.2015.00203.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Ozturk EA, Gundogdu I, Tonuk B, Kocer BG, Tombak Y, Comoglu S, et al. Bone mass and vitamin D levels in Parkinson’s disease: is there any difference between genders? J Phys Ther Sci. 2016;28(8):2204–9. doi:10.1589/jpts.28.2204.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Goodman CA, Hornberger TA, Robling AG. Bone and skeletal muscle: key players in mechanotransduction and potential overlapping mechanisms. Bone. 2015;80:24–36. doi:10.1016/j.bone.2015.04.014.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Rosen CJ. Clinical practice. Postmenopausal osteoporosis N Engl J Med. 2005;353(6):595–603. doi:10.1056/NEJMcp043801.

    Article  CAS  PubMed  Google Scholar 

  106. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson’s disease. Mov Disord. 2006;21(11):1824–30. doi:10.1002/mds.21068.

    Article  PubMed  Google Scholar 

  107. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31(3):266–300. doi:10.1210/er.2009-0024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004;116(9):634–9. doi:10.1016/j.amjmed.2003.12.029.

    Article  CAS  PubMed  Google Scholar 

  109. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. doi:10.1056/NEJMra070553.

    Article  CAS  PubMed  Google Scholar 

  110. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. 2008;88(2):491S–9S.

    CAS  PubMed  Google Scholar 

  111. DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC. Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol. 2013;39(5):458–84. doi:10.1111/nan.12020.

    Article  CAS  PubMed  Google Scholar 

  112. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21–30. doi:10.1016/j.jchemneu.2004.08.006.

    Article  CAS  PubMed  Google Scholar 

  113. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65(10):1348–52. doi:10.1001/archneur.65.10.1348.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67(7):808–11. doi:10.1001/archneurol.2010.120.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V, et al. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol. 2011;68(3):314–9. doi:10.1001/archneurol.2011.30.

    Article  PubMed  Google Scholar 

  116. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Kawasaki K, Noya M, et al. 25-Hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson’s disease. Mov Disord. 2012;27(2):264–71. doi:10.1002/mds.24016.

    Article  CAS  PubMed  Google Scholar 

  117. van den Bos F, Speelman AD, van Nimwegen M, van der Schouw YT, Backx FJ, Bloem BR et al. Bone mineral density and vitamin D status in Parkinson's disease patients. J Neurol. 2013;260(3):754–60. doi:10.1007/s00415-012-6697-x.

  118. Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson’s disease—a pilot study. Mov Disord. 2013;28(8):1133–7. doi:10.1002/mds.25405.

    Article  PubMed  Google Scholar 

  119. Chitsaz A, Maracy M, Basiri K, Izadi Boroujeni M, Tanhaei AP, Rahimi M, et al. 25-Hydroxyvitamin d and severity of Parkinson’s disease. Int J Endocrinol. 2013;2013:689149. doi:10.1155/2013/689149.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  120. Meamar R, Maracy M, Chitsaz A, Ghazvini MR, Izadi M, Tanhaei AP. Association between serum biochemical levels, related to bone metabolism and Parkinson’s disease. J Res Med Sci. 2013;18(Suppl 1):S39–42.

    PubMed  PubMed Central  Google Scholar 

  121. Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013;81(17):1531–7. doi:10.1212/WNL.0b013e3182a95818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Moghaddasi M, Mamarabadi M, Aghaii M. Serum 25-hydroxyvitamin D3 concentration in Iranian patients with Parkinson’s disease. Iran J Neurol. 2013;12(2):56–9.

  123. Liu Y, Zhang BS. Serum 25-hydroxyvitamin D predicts severity in Parkinson’s disease patients. Neurol Sci. 2014;35(1):67–71. doi:10.1007/s10072-013-1539-x.

    Article  PubMed  Google Scholar 

  124. Petersen MS, Bech S, Christiansen DH, Schmedes AV, Halling J. The role of vitamin D levels and vitamin D receptor polymorphism on Parkinson’s disease in the Faroe Islands. Neurosci Lett. 2014;561:74–9. doi:10.1016/j.neulet.2013.12.053.

    Article  CAS  PubMed  Google Scholar 

  125. Wang L, Evatt ML, Maldonado LG, Perry WR, Ritchie JC, Beecham GW, et al. Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord. 2015;30(4):560–6. doi:10.1002/mds.26117.

    Article  CAS  PubMed  Google Scholar 

  126. Jang W, Park J, Kim JS, Youn J, Oh E, Kwon KY, et al. Vitamin D deficiency in Parkinson’s disease patients with orthostatic hypotension. Acta Neurol Scand. 2015;132(4):242–50. doi:10.1111/ane.12390.

    Article  CAS  PubMed  Google Scholar 

  127. Yoon JH, Park DK, Yong SW, Hong JM. Vitamin D deficiency and its relationship with endothelial dysfunction in patients with early Parkinson’s disease. J Neural Transm (Vienna). 2015;122(12):1685–91. doi:10.1007/s00702-015-1452-y.

    Article  CAS  Google Scholar 

  128. Kwon KY, Jo KD, Lee MK, Oh M, Kim EN, Park J, et al. Low serum vitamin D levels may contribute to gastric dysmotility in de novo Parkinson’s disease. Neurodegener Dis. 2016;16(3–4):199–205. doi:10.1159/000441917.

    Article  CAS  PubMed  Google Scholar 

  129. Wang L, Maldonado L, Beecham GW, Martin ER, Evatt ML, Ritchie JC, et al. DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurol Genet. 2016a;2(3):e72. doi:10.1212/NXG.0000000000000072.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  130. Wang J, Yang D, Yu Y, Shao G, Wang Q. Vitamin D and sunlight exposure in newly-diagnosed Parkinson’s disease. Nutrients. 2016b;8(3):142. doi:10.3390/nu8030142.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  131. Shrestha S, Lutsey PL, Alonso A, Huang X, Mosley TH Jr, Chen H. Serum 25-hydroxyvitamin D concentrations in mid-adulthood and Parkinson’s disease risk. Mov Disord. 2016;31(7):972–8. doi:10.1002/mds.26573.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Gezen-Ak D, Alaylioglu M, Genc G, Gunduz A, Candas E, Bilgic B, et al. GC and VDR SNPs and vitamin D levels in Parkinson’s disease: the relevance to clinical features. NeuroMolecular Med. 2016; doi:10.1007/s12017-016-8415-9.

  133. Rimmelzwaan LM, van Schoor NM, Lips P, Berendse HW, Eekhoff EM. Systematic review of the relationship between vitamin D and Parkinson’s disease. J Parkinsons Dis. 2016;6(1):29–37. doi:10.3233/JPD-150615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Shen L, Ji HF. Associations between vitamin D status, supplementation, outdoor work and risk of Parkinson’s disease: a meta-analysis assessment. Nutrients. 2015;7(6):4817–27. doi:10.3390/nu7064817.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–56. doi:10.1016/j.gene.2004.05.014.

    Article  CAS  PubMed  Google Scholar 

  136. Puchacz E, Stumpf WE, Stachowiak EK, Stachowiak MK. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res. 1996;36(1):193–6.

    Article  CAS  PubMed  Google Scholar 

  137. Pertile RA, Cui X, Eyles DW. Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience. 2016;333:193–203. doi:10.1016/j.neuroscience.2016.07.020.

    Article  CAS  PubMed  Google Scholar 

  138. Calvello R, Cianciulli A, Nicolardi G, De Nuccio F, Giannotti L, Salvatore R, et al. Vitamin D treatment attenuates neuroinflammation and dopaminergic Neurodegeneration in an animal model of Parkinson’s disease, shifting M1 to M2 microglia responses. J NeuroImmune Pharmacol. 2016; doi:10.1007/s11481-016-9720-7.

  139. Han X, Xue L, Li Y, Chen B, Xie A. Vitamin D receptor gene polymorphism and its association with Parkinson’s disease in Chinese Han population. Neurosci Lett. 2012;525(1):29–33. doi:10.1016/j.neulet.2012.07.033.

    Article  CAS  PubMed  Google Scholar 

  140. Torok R, Torok N, Szalardy L, Plangar I, Szolnoki Z, Somogyvari F, et al. Association of vitamin D receptor gene polymorphisms and Parkinson’s disease in Hungarians. Neurosci Lett. 2013;551:70–4. doi:10.1016/j.neulet.2013.07.014.

    Article  CAS  PubMed  Google Scholar 

  141. Liu HX, Han X, Zheng XP, Li YS, Xie AM. Association of vitamin D receptor gene polymorphisms with Parkinson disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013;30(1):13–6. doi:10.3760/cma.j.issn.1003-9406.2013.01.004.

    PubMed  Google Scholar 

  142. Kim JS, Kim YI, Song C, Yoon I, Park JW, Choi YB, et al. Association of vitamin D receptor gene polymorphism and Parkinson’s disease in Koreans. J Korean Med Sci. 2005;20(3):495–8. doi:10.3346/jkms.2005.20.3.495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Lv Z, Tang B, Sun Q, Yan X, Guo J. Association study between vitamin d receptor gene polymorphisms and patients with Parkinson disease in Chinese Han population. Int J Neurosci. 2013;123(1):60–4. doi:10.3109/00207454.2012.726669.

    Article  CAS  PubMed  Google Scholar 

  144. Zhang ZT, He YC, Ma XJ, Li DY, Lu GC. Association between vitamin D receptor gene polymorphisms and susceptibility to Parkinson’s disease: a meta-analysis. Neurosci Lett. 2014;578:122–7. doi:10.1016/j.neulet.2014.06.051.

    Article  CAS  PubMed  Google Scholar 

  145. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;9:CD007146. doi:10.1002/14651858.CD007146.pub3.

    Google Scholar 

  146. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2008;23(5):631–40. doi:10.1002/mds.21922.

    Article  PubMed  Google Scholar 

  147. Protas EJ, Mitchell K, Williams A, Qureshy H, Caroline K, Lai EC. Gait and step training to reduce falls in Parkinson’s disease. NeuroRehabilitation. 2005;20(3):183–90.

    PubMed  Google Scholar 

  148. Ashburn A, Fazakarley L, Ballinger C, Pickering R, McLellan LD, Fitton C. A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(7):678–84. doi:10.1136/jnnp.2006.099333.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Noya M, Takahashi D, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr. 2013;97(5):1004–13. doi:10.3945/ajcn.112.051664.

    Article  CAS  PubMed  Google Scholar 

  150. O’Connor KM. Evaluation and treatment of osteoporosis. Med Clin North Am. 2016;100(4):807–26. doi:10.1016/j.mcna.2016.03.016.

    Article  PubMed  Google Scholar 

  151. Drake MT, Clarke BL, Lewiecki EM. The pathophysiology and treatment of osteoporosis. Clin Ther. 2015;37(8):1837–50. doi:10.1016/j.clinthera.2015.06.006.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatoloy Department, University Hospital Sierrallana, Torrelavega, Spain

    Leyre Riancho-Zarrabeitia

  2. Neurology Department, University Hospital Marqués de Valdecilla, Santander, Spain

    Manuel Delgado-Alvarado

  3. Neuroimaging Unit, Valdecilla Biomedical Research Institute (IDIVAL), University Hospital Marqués de Valdecilla, Santander, Spain

    Manuel Delgado-Alvarado

Authors
  1. Leyre Riancho-Zarrabeitia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel Delgado-Alvarado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manuel Delgado-Alvarado.

Ethics declarations

Financial Support

This work received no specific funding.

Conflict of Interest

Authors declare they do not have any conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riancho-Zarrabeitia, L., Delgado-Alvarado, M. Bone Health in Parkinson’s Disease. Clinic Rev Bone Miner Metab 15, 99–114 (2017). https://doi.org/10.1007/s12018-017-9232-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12018-017-9232-x

Keywords

Search

Navigation